PharmaEngine Inc 2023 SR
The report details PharmaEngine's 2023 sustainability efforts, focusing on its 'Virtual Pharmaceutical Company' model for oncology drug development. Key highlights include the expansion of ONIVYDE for first-line pancreatic cancer treatment and progress in PEP07 clinical trials. The company achieved ISO 27001 certification for cyber security and conducted its first employee satisfaction survey, reaching the 73rd percentile. Environmental initiatives focused on GHG inventory (Scope 1 and 2) and water/waste reduction targets. Social engagement included hosting five health education seminars for pancreatic cancer patients across Taiwan.
Company: PharmaEngine Inc
Sector: Health Care
Country: Taiwan
Year: 2023
Type: SR
Pages: 76
PharmaEngine Inc
Sustainability Report
The report details PharmaEngine's 2023 sustainability efforts, focusing on its 'Virtual Pharmaceutical Company' model for oncology drug development. Key highlights include the expansion of ONIVYDE for first-line pancreatic cancer treatment and progress in PEP07 clinical trials. The company achieved ISO 27001 certification for cyber security and conducted its first employee satisfaction survey, reaching the 73rd percentile. Environmental initiatives focused on GHG inventory (Scope 1 and 2) and water/waste reduction targets. Social engagement included hosting five health education seminars for pancreatic cancer patients across Taiwan.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Published
Aug 2, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Women in Management
Employees